The board of ERIS Lifesciences at its meeting held on 24 November 2025 has approved the acquisition of balance 30% of the total share capital of Swiss Parenterals, a subsidiary of the Company.
Further, the board has approved the issuance of up to 23,06,372 equity shares of the Company on preferential basis to discharge the consideration for acquisition of 30% stake in Swiss Parenterals.
Copyright © 2025 M&A Critique!. All pages of the Website are subject to our terms and conditions and privacy policy. You must not reproduce, duplicate, copy, sell, resell or exploit any material on the Website for any commercial purposes.We have made a sincere effort to ensure that all photographs used on this website are either freely available in the public domain or used with permission. If you believe your work is being used inappropriately, please let us know and we will address the matter immediately.
[ultimatemember form_id=140]